US › Healthcare

Greenwich Lifesciences Inc (GLSI)

US · Healthcare · Biotechnology

$14.35+5.98%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$3,558
Revenue YoY
-1.5%
Net profit
$-5.7M
Profit YoY
-106.1%
EPS
$-0.39
EPS estimate
$-0.32
Net margin
-158,997.7%

EPS came in at -0.39 against a street estimate of -0.32 — a miss of 21.9%.

Key statistics

Market cap
$198.2M
Forward P/E
0.0
P/B
37.85
Book value
$0.36
EPS (TTM)
$-1.61
52-week high
$34.10
52-week low
$7.78
50-day MA
$20.97
200-day MA
$20.23
Beta
1.39

Analyst view

Analysts rate Greenwich Lifesciences Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $57.00.

Shareholding

Insiders
47.91%
Institutions
12.54%

Largest institutional holders

FundStake
BlackRock Inc2.96%
Vanguard Capital Management, LLC2.03%
Geode Capital Management, LLC1.06%
State Street Corp0.91%
Nuveen, LLC0.60%
Northern Trust Corp0.51%
Vanguard Portfolio Management, LLC0.40%
Bank of New York Mellon Corp0.32%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Greenwich Lifesciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.